Bavarian Nordic starts human tests of new HIV vaccine  

The Danish biotech firm initiates clinical trials to assess the safety and immunogenicity of its MVA-BN polytope vaccine
Danish biotech firm Bavarian Nordic has announced in a press release that it has initiated a Phase I and Phase I/II clinical trial to evaluate the safety and immunogenicity of its MVA-BN polytope vaccine for HIV. Both healthy and HIV-infected subjects are participating in the studies.
MVA-BN polytope is the second of the company’s three vaccine candidates to enter clinical trials. Bavarian Nordic sees strong potential in the vaccine as it is designed to have both a prophylactic and therapeutic effect. Its first vaccine – MVA nef – is being developed as a therapeutic agent only.
Bavarian Nordic is currently preparing to file an Investigational New Drug Application with the FDA, with a view to starting two additional Phase II studies with MVA-BN polytope in the US in H1 2007.
According to the WHO, an estimated 4 million people are infected with HIV every year. More than 95% of all new infections occur in developing countries, making HIV among the most serious threats not only to global health, but to global development.
Link > Bavarian Nordic  

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×